AbbVie (ABBV) announced that it has completed its acquisition of ImmunoGen (IMGN). With the completion of the acquisition, ImmunoGen is now part of AbbVie. AbbVie has acquired all outstanding ImmunoGen common stock for $31.26 per share. It is expected that ImmunoGen’s common stock will cease to trade on the NASDAQ stock exchange prior to market open on February 12. AbbVie expects its acquisition of ImmunoGen to be accretive to AbbVie’s diluted EPS beginning in 2027 and significantly accretive over the long-term.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ABBV:
- AbbVie Completes Acquisition of ImmunoGen
- AbbVie price target raised to $195 from $180 at Truist
- AbbVie price target raised to $172 from $165 at UBS
- AbbVie price target raised to $195 from $187 at BMO Capital
- AbbVie price target lowered to $196 from $197 at Morgan Stanley
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue